Literature DB >> 28833355

Serum chemerin levels are inversely associated with renal function in a general population.

Stephanie Zylla1,2, Rainer Rettig3, Henry Völzke2,4,5, Karlhans Endlich6, Matthias Nauck1,2, Nele Friedrich1,2,7.   

Abstract

OBJECTIVE: Chemerin has been found to be highly expressed in the kidneys of rodents and has been suggested to affect metabolic syndrome (MetS)-related phenotypes which are in turn related to kidney damage. Only few clinical studies have addressed the relation between circulating chemerin and renal function in humans, and no population-based analyses have yet been performed. The potential influence of MetS-related phenotypes on the assumed association has been largely neglected. We aimed to investigate the association of serum chemerin with renal function in a general population with special regard to possible interactions between chemerin and metabolic phenotypes. DESIGN, PATIENTS AND MEASUREMENTS: Linear and logistic regression models were applied to analyse data from 4082 subjects of the German Study of Health in Pomerania. Main outcomes included estimated glomerular filtration rate (eGFR), serum creatinine and cystatin C and chronic kidney disease.
RESULTS: Inverse associations of chemerin with eGFR were observed. The components of the MetS emerged as modulating factors in this relation and enhanced the association. Logistic regression models confirmed the relation between chemerin and eGFR and revealed that each increase in chemerin per 25 ng/mL was associated with an about threefold higher odds of chronic kidney disease [odds ratio 2.72 (95% confidence interval 2.26-3.29)].
CONCLUSIONS: Our results demonstrate a strong inverse association between serum chemerin levels and renal function. This association might be explained by MetS-related phenotypes, which lead to renal damage and are associated with increased chemerin levels and/or an impaired renal elimination of chemerin by diseased kidneys.
© 2017 John Wiley & Sons Ltd.

Entities:  

Keywords:  adipokines; blood circulation; chronic kidney disease; diabetes mellitus; dyslipidaemia; hypertension; obesity

Mesh:

Substances:

Year:  2017        PMID: 28833355     DOI: 10.1111/cen.13449

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  8 in total

Review 1.  Immunologic and endocrine functions of adipose tissue: implications for kidney disease.

Authors:  Qingzhang Zhu; Philipp E Scherer
Journal:  Nat Rev Nephrol       Date:  2017-12-04       Impact factor: 28.314

2.  Parental Dietary Protein Source and the Role of CMKLR1 in Determining the Severity of Dahl Salt-Sensitive Hypertension.

Authors:  Justine M Abais-Battad; Hayley Lund; Daniel J Fehrenbach; John Henry Dasinger; Ammar J Alsheikh; David L Mattson
Journal:  Hypertension       Date:  2019-02       Impact factor: 10.190

3.  Chemerin/ChemR23 axis promotes inflammation of glomerular endothelial cells in diabetic nephropathy.

Authors:  Jin Shang; Luyao Wang; Ya Zhang; Shiyi Zhang; Lina Ning; Jifang Zhao; Genyang Cheng; Dong Liu; Jing Xiao; Zhanzheng Zhao
Journal:  J Cell Mol Med       Date:  2019-02-19       Impact factor: 5.310

Review 4.  Adipocytokines: Are they the Theory of Everything?

Authors:  Pierre S Maximus; Zeina Al Achkar; Pousette F Hamid; Syeda S Hasnain; Cesar A Peralta
Journal:  Cytokine       Date:  2020-06-16       Impact factor: 3.861

5.  Chemerin inhibits vascular calcification through ChemR23 and is associated with lower coronary calcium in chronic kidney disease.

Authors:  M Carracedo; A Witasp; A R Qureshi; A Laguna-Fernandez; T Brismar; P Stenvinkel; M Bäck
Journal:  J Intern Med       Date:  2019-07-07       Impact factor: 8.989

6.  Chemerin as a Driver of Hypertension: A Consideration.

Authors:  David J Ferland; Adam E Mullick; Stephanie W Watts
Journal:  Am J Hypertens       Date:  2020-11-03       Impact factor: 2.689

7.  Determinants of elevated chemerin as a novel biomarker of immunometabolism: data from a large population-based cohort.

Authors:  Liselot Koelman; Robin Reichmann; Claudia Börnhorst; Matthias B Schulze; Cornelia Weikert; Ronald Biemann; Berend Isermann; Andreas Fritsche; Krasimira Aleksandrova
Journal:  Endocr Connect       Date:  2021-09-20       Impact factor: 3.335

8.  Alpha-lipoic acid could attenuate the effect of chemerin-induced diabetic nephropathy progression.

Authors:  Hong Zhang; Jiawei Mu; Jinqiu Du; Ying Feng; Wenhui Xu; Mengmeng Bai; Huijuan Zhang
Journal:  Iran J Basic Med Sci       Date:  2021-08       Impact factor: 2.699

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.